Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meta-analysis
100%
Chronic Myeloid Leukemia
73%
Acute Myeloid Leukemia
69%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
63%
Overall Survival
49%
Leukemia Patients
39%
Tyrosine Kinase Inhibitor
39%
Randomized Controlled Trial
38%
Relative Risk
36%
Multiple Myeloma
33%
Confidence Interval
33%
Rituximab
32%
Acute Leukemia
32%
Hematological Malignancies
29%
Relapsed/refractory
29%
Chronic Lymphocytic Leukemia
25%
Progression-free Survival
25%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Israel
25%
Chemotherapy
24%
Imatinib
23%
Newly Diagnosed
23%
Hazard Ratio
23%
Oncology Patients
22%
Venous Thromboembolism
21%
Infectious Complications
21%
95% Confidence Interval
21%
Lymphoma Patients
20%
Direct Oral Anticoagulants
20%
Anticoagulation
19%
Thrombocytopenia
18%
Positron Emission Tomography/computed Tomography (PET/CT)
17%
Adverse Events
17%
Venetoclax
17%
Bone Marrow
17%
Patients with Hematological Malignancies
17%
All-cause Mortality
16%
Adult Patients
16%
Retrospective Cohort Study
16%
Acute Lymphoblastic Leukemia
16%
Multiple Myeloma Patients
16%
Leukemia
16%
Treatment Lines
15%
Complete Remission
15%
Human Telomerase Reverse Transcriptase (hTERT)
15%
Dasatinib
14%
Lymphoma
14%
Single-center Experience
14%
Hodgkin Lymphoma
14%
Israeli
14%
Medicine and Dentistry
Diseases
52%
Overall Survival
49%
Chronic Myelogenous Leukemia
47%
Systematic Review
47%
Acute Myeloid Leukemia
44%
Meta-Analysis
39%
Multiple Myeloma
39%
Tyrosine-Kinase Inhibitor
32%
Hematopoietic Cell
30%
Chemotherapy
29%
Cell Transplantation
29%
Adverse Event
28%
Diffuse Large B-Cell Lymphoma
25%
Malignant Neoplasm
25%
Positron Emission Tomography-Computed Tomography
25%
Progression Free Survival
24%
Retrospective Study
24%
Hematologic Malignancy
23%
Venous Thromboembolism
22%
Hodgkin's Lymphoma
20%
Thrombocytopenia
19%
Retrospective Cohort Study
19%
Myelodysplastic Syndrome
18%
Acute Promyelocytic Leukemia
17%
Rituximab
16%
Infection
16%
Acute Leukemia
15%
Dasatinib
15%
Anticoagulation
15%
Hazard Ratio
14%
Randomized Controlled Trial
14%
Tretinoin
14%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Myelofibrosis
14%
Venetoclax
13%
Observational Study
13%
Ruxolitinib
13%
Azacitidine
13%
Platelet
13%
Thrombosis
13%
Computer Assisted Tomography
13%
Non-Hodgkin Lymphoma
12%
Nilotinib
12%
Autologous Stem Cell Transplantation
12%
Anemia
12%
Imatinib
12%
Ponatinib
12%
Cytarabine
11%
Compassionate Use
11%
Salvage Therapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
61%
Diseases
48%
Infection
44%
Overall Survival
43%
Randomized Controlled Trial
43%
Protein Tyrosine Kinase Inhibitor
40%
Chemotherapy Regimens
39%
Acute Myeloid Leukemia
38%
Multiple Myeloma
38%
Hematologic Malignancy
35%
Adverse Event
35%
Malignant Neoplasm
35%
Imatinib
32%
Rituximab
31%
Chronic Lymphatic Leukemia
29%
Cohort Study
25%
Remission
23%
Progression Free Survival
22%
Diffuse Large B Cell Lymphoma
18%
Retinoic Acid
17%
Promyelocytic Leukemia
17%
Neutropenia
17%
Leukemia
17%
Direct Oral Anticoagulant
16%
Thrombocytopenia
15%
Venous Thromboembolism
15%
All Cause Mortality
14%
Atrial Fibrillation
14%
Rat
14%
Immunoglobulin
14%
Infectious Complication
13%
Obinutuzumab
13%
Interferon
13%
Neoplasm
13%
Bleeding
12%
Thalidomide
12%
Lenalidomide
12%
Acute Leukemia
11%
Arterial Thromboembolism
11%
Retrospective Study
11%
Venetoclax
10%
Bendamustine
10%
Telomerase
10%
Methotrexate
10%
Myelofibrosis
10%
Ruxolitinib
10%
Aplastic Anemia
10%
Colony Stimulating Factor
10%
Gilteritinib
10%
Sialyltransferase
10%